Mechanisms and risk factors of thrombosis in cancer, Critical Reviews in Oncology, vol.118, pp.79-83, 2017. ,
Predicting recurrent venous thromboembolism in cancer: is it possible?, Thrombosis Research. 1 mai, vol.133, pp.17-22, 2014. ,
Clinical challenges in patients with cancer-associated thrombosis: Canadian expert consensus recommendations, Curr Oncol. févr, vol.22, issue.1, pp.49-59, 2015. ,
The Role of Direct Oral Anticoagulants in Treatment of CancerAssociated Thrombosis, Cancers. août, vol.10, issue.8, p.271, 2018. ,
International clinical practice guidelines including guidance for direct oral anticoagulants in the treatment and prophylaxis of venous thromboembolism in patients with cancer. The Lancet Oncology, vol.17, pp.452-66, 2016. ,
Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update, Journal of Clinical Oncology. 10 juin, vol.31, issue.17, pp.2189-204, 2013. ,
Thrombose et Cancer -Recommandation ,
Treatment of venous thromboembolism in patients with cancer: A network meta-analysis comparing efficacy and safety of anticoagulants, Thrombosis Research. 1 sept, vol.136, issue.3, pp.582-591, 2015. ,
,
Dictionnaire médical de l'Académie de Médecine ,
Qu'est-ce que le cancer? ,
Les stades du cancer ,
,
Les grades du cancer ,
,
Thrombose hémostase et cancer : les mécanismes physiopathologiques en jeu, Oncologie. déc, vol.14, issue.12, pp.638-681, 2012. ,
,
,
, Fédération Française de Cardiologie. Embolie pulmonaire, 2016.
,
Cancer associated thrombosis: risk factors and outcomes, Thrombosis Research. avr, vol.140, pp.12-19, 2016. ,
Activation et inhibition de la coagulation : que se passe-t-il en cas de coagulopathie intravasculaire disséminée ? Réanimation, vol.11, pp.584-90, 2002. ,
Physiologie et sémiologie de l'hémostase ,
,
Physiologie de l'hémostase ,
,
Tumour and microparticle tissue factor expression and cancer thrombosis, Thrombosis Research. févr, vol.131, issue.2, pp.109-124, 2013. ,
La maladie thromboembolique veineuse chez les patients atteints d'une hémopathie maligne État des lieux sur l'ampleur du problème, Hématologie. 1 janv, vol.25, issue.1, pp.16-28, 2019. ,
Traitement des maladies thromboemboliques veineuses dans le cancer : étude observationnelle sur 220 patients, 2016. ,
Maladie Thrombo-Embolique Veineuse et Cancer. La lettre du médecin vasculaire, pp.28-39, 2016. ,
NETs and cancer, Thrombosis Research. avr, vol.164, pp.148-52, 2018. ,
The mechanisms of cancer-associated thrombosis, Thrombosis Research. févr, vol.135, pp.8-11, 2015. ,
Les thrombophilies constitutionnelles ,
Mutation g.20210 du gène de la prothrombine ,
,
,
, Bull Acad Natl Med, vol.187, issue.1, pp.32-33, 2003.
Predictors of venous thromboembolism recurrence and bleeding among active cancer patients: a population-based cohort study, Blood. 19 juin, vol.123, issue.25, pp.3972-3980, 2014. ,
Risk of venous thromboembolism in patients with cancer treated with Cisplatin: a systematic review and metaanalysis, J Clin Oncol. 10 déc, vol.30, issue.35, pp.4416-4442, 2012. ,
Cancers, thromboses veineuses et traitements antiangiogéniques, VEGF actu, issue.19, p.3, 2010. ,
Scores cliniques pour le risque de récidive de maladie veineuse thromboembolique (MVTE) et pour les relations cancer-MVTE*. Revue Médicale Suisse, vol.12, pp.363-370, 2016. ,
Cancer prognosis in patients with venous thromboembolism (VTE) and patients with clinical and laboratory biomarkers predictive of VTE risk, Thromb Res, vol.164, issue.1, pp.19-22, 2018. ,
Les anticoagulants en France en 2014: état des lieux, synthèse et surveillance, 2014. ,
Rapport sur les anticoagulants oraux directs (AOD) (antérieurement appelés « nouveaux anticoagulants oraux » ou NACO), juin, vol.198, issue.6, pp.1157-95, 2014. ,
,
Les nouveaux anticoagulants oraux : modalités de prescription et perception par les généralistes, 2014. ,
Monographie PRADAXA 75mg ,
,
Monographie ELIQUIS 5mg ,
,
Monographie XARELTO 10mg ,
,
Place des nouveaux anticoagulants oraux directs, Revue Médicale Suisse, vol.10, pp.1562-1569, 2014. ,
New Oral Anticoagulants and the Cancer Patient, The Oncologist. 1 janv, vol.19, issue.1, pp.82-93, 2014. ,
Drug Interactions of Direct-Acting Oral Anticoagulants, Drug Safety. sept, vol.39, issue.9, pp.841-846, 2016. ,
Direct oral anticoagulants: Current indications and unmet needs in the treatment of venous thromboembolism, Pharmacol Res, vol.118, pp.33-42, 2017. ,
Safe and effective use of rivaroxaban for treatment of cancer-associated venous thromboembolic disease: a prospective cohort study, J Thromb Thrombolysis. févr, vol.43, issue.2, pp.166-71, 2017. ,
Direct oral anticoagulants for the treatment of venous thromboembolism in cancer patients: Potential for drug-drug interactions, Crit Rev Oncol Hematol. déc, vol.132, pp.169-79, 2018. ,
Résumé des Caractéristiques du Produit Rivaroxaban 15mg ,
Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation, Am J Cardiol. 1 août, vol.110, issue.3, pp.453-60, 2012. ,
Direct oral anticoagulants in patients with VTE and cancer: a systematic review and meta-analysis, Chest. févr, vol.147, issue.2, pp.475-83, 2015. ,
How I treat cancer-associated venous thromboembolism, Blood. 24 janv, vol.133, issue.4, pp.291-299, 2019. ,
Pharmacokinetic variability of anticoagulants in patients with cancer-associated thrombosis: Clinical consequences, Crit Rev Oncol Hematol. sept, vol.129, pp.102-114, 2018. ,
Comparative Pharmacodynamic Assessment of the Antiangiogenesis Activity of Heparin and Low-Molecular-Weight Heparin Fractions: Structure-Function Relationship, Clinical and Applied Thrombosis/Hemostasis. janv, vol.19, issue.1, pp.48-54, 2013. ,
Anti-cancer properties of low-molecular-weight heparin: Preclinical evidence, Thrombosis and Haemostasis, vol.102, issue.08, pp.258-67, 2009. ,
Comparative effectiveness and safety of direct oral anticoagulants (DOACs) versus conventional anticoagulation for the treatment of cancerrelated venous thromboembolism: A retrospective analysis, Thrombosis Research. 1 févr, vol.150, pp.86-95, 2017. ,
Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial, J Thromb Haemost. déc, vol.13, issue.12, pp.2187-91, 2015. ,
Role of direct oral anticoagulants in the treatment of cancer-associated venous thromboembolism: guidance from the SSC of the ISTH, Journal of Thrombosis and Haemostasis, vol.16, issue.9, pp.1891-1895, 2018. ,
Treatment of cancer-associated venous thromboembolism in the age of direct oral anticoagulants, Annals of Oncology. 1 juin, vol.30, issue.6, pp.897-907, 2019. ,
Direct Oral Anticoagulant Drugs: On the Treatment of Cancer-Related Venous Thromboembolism and their Potential Anti-Neoplastic Effect, Cancers (Basel). 5 janv, vol.11, issue.1, 2019. ,
Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D), J Clin Oncol. 10 juill, vol.36, issue.20, pp.2017-2040, 2018. ,
Direct Oral Anticoagulants and Cancer-Associated Thrombosis Management. Where Do We Stand in 2019?, Clin Appl Thromb Hemost. déc, vol.25, pp.1-7, 2019. ,
Commission de la Transparence ELIQUIS 2.5 -5mg ,
Oral apixaban for the treatment of acute venous thromboembolism, N Engl J Med. 29 août, vol.369, issue.9, pp.799-808, 2013. ,
URL : https://hal.archives-ouvertes.fr/hal-00932477
Acute haemorrhagic tamponade in cancer patients receiving direct oral anticoagulant: case series, Eur Heart J Case Rep. 20 déc, vol.1, issue.2, 2017. ,
Apixaban for the prevention of thromboembolism in immunomodulatory-treated myeloma patients: Myelaxat, a phase 2 pilot study, American Journal of Hematology, vol.94, issue.6, pp.635-675, 2019. ,